RESPANA THERAPEUTICS RECEIVES SUPPORT FROM PENNSYLVANIA’S COVID-19 VACCINES, TREATMENTS AND THERAPIES (CV-VTT) PROGRAM
Funding Will Be Used to Advance the Company’s Novel Monoclonal Antibody
Philadelphia, PA – September 1, 2020. Respana Therapeutics is pleased to announce that it was one of 23 enterprises selected by the Commonwealth of Pennsylvania to receive a portion of the $10 million in grant funding made available through the COVID-19 Vaccines, Treatments and Therapies (CV-VTT) program. The program supports the rapid advancement of vaccines, treatments and therapies by qualified biotechnology entities in response to the COVID-19 pandemic.
Respana is developing novel therapeutic monoclonal antibodies for the treatment of the adverse effects resulting from viral infections of the lung, including Influenza A and COVID-19. Post-infection complications are a leading cause of morbidity and mortality in those with acute respiratory illnesses.
“Unlike most therapies aimed at the flu and COVID-19 ours works with the host – that is, the patient’s own immune system,” said Andy Agrawal, VP Business Development. “This has the potential to confer a number of advantages, including avoidance of drug resistance. It also means that this therapy could be used to both prevent and treat some of the most serious complications of lung infections.”
Respana Therapeutics is a spinout of Penn State Milton S. Hershey College of Medicine.
About Respana Therapeutics
Respana Therapeutics, Inc., is an early stage spin out from Penn State University developing therapeutics that repair inflammatory conditions associated with viral infections of the lung including influenza A and COVID-19. Visit www.respana-theraputics.com for more information.
# # #
Media Contact: Michele Washko
Respana Therapeutics, Inc.
mwashko@respana-therapeutics.com